Foundation Medicine, based in Cambridge, MA, has announced the commercial launch of FoundationACT (Assay for Circulating Tumor DNA), a blood-based genomic profiling assay for cancer patients who are not candidates for a tissue-based biopsy. The new test is designed to identify and quantify DNA from tumor cells that may be present at an early stage but have no known prognosis.
Foundation Medicine, based in Cambridge, MA, has announced the commercial launch of FoundationACT (Assay for Circulating Tumor DNA), a blood-based genomic profiling assay for cancer patients who are not candidates for a tissue-based biopsy. The company claims that it has overcome many of the clinical limitations of other liquid biopsy tests and allows the company to be the "go-to resource for a complete, end-to-end offering of comprehensive molecular information solutions."